Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 12/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989442 | 0.95 | KDM4E (0.43) | L3MBTL1GRM5NPC1RAB9AHSD11B1 | |
| SCHEMBL2818567 | 0.91 | L3MBTL1 (0.47) | L3MBTL1GRM5NPC1RAB9AHSD11B1 | |
| SCHEMBL990869 | 0.90 | GRM5 (0.48) | L3MBTL1GRM5NPC1RAB9AMEN1 | |
| SCHEMBL990340 | 0.90 | L3MBTL1 (0.59) | L3MBTL1GRM5NPC1RAB9AMEN1 | |
| SCHEMBL990083 | 0.90 | L3MBTL1 (0.47) | L3MBTL1GRM5NPC1RAB9AMEN1 | |
| SCHEMBL990807 | 0.89 | GRM5 (0.52) | L3MBTL1GRM5NPC1RAB9AHSD11B1 | |
| SCHEMBL3284072 | 0.88 | GRM5 (0.57) | L3MBTL1GRM5NPC1RAB9A | |
| SCHEMBL990125 | 0.88 | GRM5 (0.57) | L3MBTL1GRM5NPC1RAB9A | |
| SCHEMBL3432735 | 0.88 | L3MBTL1 (0.45) | L3MBTL1GRM5NPC1RAB9AMEN1 | |
| SCHEMBL991458 | 0.88 | L3MBTL1 (0.45) | L3MBTL1GRM5NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272929-A1 | ORGANIC COMPOUNDS | UMBRICHT DANIEL (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2826478-A1 | COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20140194423-A1 | COMBINATION PRODUCTS | GOMEZ-MANCILLA BALTAZAR (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8703809-B2 | Combination products | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| WO-2013131981-A1 | PREDICTIVE MARKERS USEFUL IN THE DIAGNOSIS AND TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2013-09-12 | — | — | WO | disclosed |
| US-20130052644-A1 | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) | NOVARTIS AG (CH) | 2013-02-28 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120122878-A1 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG | 2010-04-22 | — | — | US | disclosed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009047303-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047296-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OP PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| US-20080214673-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| EP-1877365-A1 | ACETYLENE DERIVATIVES | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114262-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NAT1, NAT10, F12 | L3MBTL1 4519/4885GRM5 3794/4885NPC1 677/4885 |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | L3MBTL1 3004/4885GRM5 1/4885NPC1 1564/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | L3MBTL1 2936/4885GRM5 1/4885NPC1 1500/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | L3MBTL1 2936/4885GRM5 1/4885NPC1 1500/4885 |
| US-20120122878-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | L3MBTL1 1867/4885GRM5 1/4885NPC1 3333/4885 |
| US-20150272929-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | L3MBTL1 2109/4885GRM5 1/4885NPC1 1076/4885 |
| US-20140194423-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | L3MBTL1 1867/4885GRM5 1/4885NPC1 3333/4885 |
| US-20080214673-A1 | Acetylene Derivatives | NAT1, NAT10, F12 | L3MBTL1 4519/4885GRM5 3794/4885NPC1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.